Faculty

Back to Index
William Stohl, MD, PhD
Professor of Medicine
Chief, Division of Rheumatology
Medicine
HMR 711 Health Sciences Campus Los Angeles
+1 323 442 1959

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren's syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003

University of Pennsylvania School of Medicine: Upjohn Award, 1979

Publications

Maternal Serum B-Cell Activating Factor Levels: Candidate Early Biomarker for Hypertensive Disorders of Pregnancy. Hypertension. 2017 Sep 18. View in: PubMed

Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE). Expert Rev Clin Immunol. 2017 Jun; 13(6):623-633. View in: PubMed

A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens. J Clin Invest. 2017 May 01; 127(5):1651-1663. View in: PubMed

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017 May; 69(5):1016-1027. View in: PubMed

Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study. Clin Rheumatol. 2017 Mar; 36(3):507-516. View in: PubMed

B cell-independent contribution of BAFF to murine autoimmune disease. Clin Immunol. 2016 Nov; 172:111-116. View in: PubMed

Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors. Arthritis Rheumatol. 2015 Sep; 67(9):2523-35. View in: PubMed

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215. View in: PubMed

A dendritic-cell-stromal axis maintains immune responses in lymph nodes. Immunity. 2015 Apr 21; 42(4):719-30. View in: PubMed

Editorial: the BAFFling immunology of systemic lupus erythematosus: beyond B cells. Arthritis Rheumatol. 2015 Mar; 67(3):612-5. View in: PubMed

APRIL mediates peritoneal B-1 cell homeostasis. Immunol Lett. 2014 Aug; 160(2):120-7. View in: PubMed

Tear cathepsin S as a candidate biomarker for Sjögren's syndrome. Arthritis Rheumatol. 2014 Jul; 66(7):1872-81. View in: PubMed

Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc? receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014 May; 66(5):1153-64. View in: PubMed

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014 Apr; 18(4):473-89. View in: PubMed

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9. View in: PubMed

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med. 2014 Jan 13; 211(1):45-56. View in: PubMed

Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2013 Dec; 9(12):705-20. View in: PubMed

BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand. J Immunol. 2013 Aug 01; 191(3):1154-63. View in: PubMed

Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ. 2013 Jul; 22(7):807-23. View in: PubMed

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May; 40(5):579-89. View in: PubMed

Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum. 2013 Apr; 65(4):1043-54. View in: PubMed

Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2013 Feb; 65(2):299-303. View in: PubMed

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012 Aug; 39(8):1632-40. View in: PubMed

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis. 2012 Aug; 71(8):1289-96. View in: PubMed

Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. 2012 Aug; 14(4):303-9. View in: PubMed

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jul; 64(7):2328-37. View in: PubMed

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012 May; 64(5):1610-9. View in: PubMed

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012 Mar; 71(3):351-7. View in: PubMed

The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012 Jan 09; 30(1):69-77. View in: PubMed

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30. View in: PubMed

Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011 Jul 06; 13(4):228. View in: PubMed

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol. 2011 May; 23(3):305-10. View in: PubMed

B Cell and BAFF dependence of IFN-a-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol. 2011 Apr 15; 186(8):4984-93. View in: PubMed

Antibody-mediated coengagement of Fc?RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 01; 186(7):4223-33. View in: PubMed

BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One. 2011; 6(8):e23629. View in: PubMed

Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum. 2010 Aug; 62(8):2432-42. View in: PubMed

Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity. 2010 Feb; 43(1):84-97. View in: PubMed

Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010 Feb; 62(2):392-401. View in: PubMed

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther. 2010; 12(2):111. View in: PubMed

B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum. 2009 Nov; 60(11):3400-9. View in: PubMed

Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol. 2009 Nov 01; 183(9):6021-9. View in: PubMed

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78. View in: PubMed

Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51. View in: PubMed

Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol. 2009 Feb 15; 182(4):2532-41. View in: PubMed

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther. 2009; 11(5):R143. View in: PubMed

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008 Aug; 58(8):2453-9. View in: PubMed

Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol. 2008 Jul 01; 181(1):833-41. View in: PubMed

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109. View in: PubMed

New and promising treatments for rheumatoid arthritis. Am J Orthop (Belle Mead NJ). 2007 Jul; 36(7 Suppl):18-23. View in: PubMed

Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006 Dec; 6(4):351-8. View in: PubMed

Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI). Biochem Biophys Res Commun. 2006 Oct 20; 349(2):838-45. View in: PubMed

B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol. 2006 Oct; 121(1):1-12. View in: PubMed

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006 Aug 15; 177(4):2671-80. View in: PubMed

TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol. 2006 Mar 15; 176(6):3321-9. View in: PubMed

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006 Mar; 54(3):723-32. View in: PubMed

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006; 8(1):R6. View in: PubMed

Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II. Clin Immunol. 2005 Sep; 116(3):257-64. View in: PubMed

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 2005 Jul; 52(7):2080-91. View in: PubMed

BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun. 2005; 8:289-304. View in: PubMed

Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol. 2004 Oct; 155(1-2):161-71. View in: PubMed

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2004 Sep; 63(9):1096-103. View in: PubMed

MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol. 2004 Jul; 16(7):895-904. View in: PubMed

Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice. Arthritis Rheum. 2004 Jul; 50(7):2227-39. View in: PubMed

Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets. 2004 Jun; 8(3):177-89. View in: PubMed

A therapeutic role for BLyS antagonists. Lupus. 2004; 13(5):317-22. View in: PubMed

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003 Dec; 48(12):3475-86. View in: PubMed

In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens. Clin Immunol. 2003 Sep; 108(3):182-9. View in: PubMed

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003 Apr; 48(4):982-92. View in: PubMed

SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther. 2003; 5(3):136-8. View in: PubMed

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol. 2002 Oct 15; 169(8):4314-21. View in: PubMed

Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr Opin Rheumatol. 2002 Sep; 14(5):522-8. View in: PubMed

B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol. 2002 Aug; 104(2):115-22. View in: PubMed

B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep. 2002 Aug; 4(4):345-50. View in: PubMed

Powered bySC CTSI